[Trandolapril in the prevention of the sequelae of left ventricular systolic dysfunction after acute myocardial infarct].
Left ventricle systolic dysfunction and congestive heart failure after AMI are still a great problem in cardiology. Introduction of angiotensin converting enzyme (ACE) inhibitors after AMI has been a new step in therapy of the left ventricle systolic disfunction. Some long term studies have proved influence of ACE inhibitors on reduction of mortality, severe congestive heart failure (CHF), and reinfarction. The importance of administration of a remedy once daily has been emphasized, and the pharmacokinetics and pharmacodynamics of trandolapril in the left ventricle dysfunction and CHF has been described. TRACE study proved influence of long-term once daily administration of trandolapril on significant reduction of total and cardiovascular mortality, reduction of sudden death, reduction of severe and resistant CHF and reduction or relay of reinfarction. A good risk/benefit ratio has been found.
Buksa
M
M
Klinika za bolesti srca, Klinicki centar Univerziteta u Sarajevu.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril